Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
Grants for cancer research projects using imaging and liquid biopsies to monitor therapy responses and resistance emergence in patients.
Funder: National Institutes of Health
Due Dates: May 7, 2025 (AIDS) | June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | January 7, 2026 (AIDS) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | May 7, 2026 (AIDS) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision) | September 7, 2026 (AIDS) | October 5, 2026 (New) | November 5, 2026 (Renewal/Resubmission/Revision) | January 7, 2027 (AIDS) | February 5, 2027 (New) | March 5, 2027 (Renewal/Resubmission/Revision) | May 7, 2027 (AIDS) | June 5, 2027 (New) | July 5, 2027 (Renewal/Resubmission/Revision) | September 7, 2027 (AIDS) | October 5, 2027 (New) | November 5, 2027 (Renewal/Resubmission/Revision) | January 7, 2028 (AIDS)
Funding Amounts: Up to $500,000 direct costs per year, for a maximum project period of 5 years; actual budget should reflect project needs.
Summary: Supports research integrating imaging and fluid-based (liquid biopsy) tumor monitoring during cancer therapy to optimize assessment of treatment response and resistance.
Key Information: Clinical trial proposals are optional; non-domestic (non-U.S.) entities are not eligible to apply.
Description
This opportunity, offered by the National Cancer Institute (NCI) at NIH, funds R01 research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients. The goal is to determine the optimal use of these modalities for characterizing therapy response and/or the emergence of resistance. The initiative aims to foster collaboration among imaging scientists, liquid biopsy assay developers, and clinical researchers to advance precision medicine in oncology.
Projects should focus on integrating and analyzing imaging and liquid biopsy data in one or more therapeutic settings, such as:
- Clinical trials monitoring active treatment for first recurrence or advanced disease
- First-line therapy in aggressive or advanced cancers
- Retrospective analyses of existing studies using both modalities
The long-term objective is to improve the accuracy and timeliness of treatment response assessment and early detection of resistance, ultimately informing therapeutic strategies.
